Our locations are open for appointments and procedures. See how we're providing safe in-person care and telemedicine visits.

(Nuestras facilidades están abiertas para citas y procedimientos. Vea cómo brindamos atención segura en persona y visitas por medio de telemedicina.)

Learn More (Aprenda Más)
800-TEMPLE-MED Schedule Appointment

Dr. Kamel Khalili and Lewis Katz School of Medicine Team Will Lead Project Evaluating Medication’s Effect on Coronaviruses

View All News

Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology and the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), will lead a project at LKSOM evaluating the medication Piclidenoson and its effect on the viral load of coronaviruses in a mammalian cell model system. Piclidenoson is currently undergoing a Phase III clinical trial to treat rheumatoid arthritis. It has previously demonstrated anti-viral activity against HIV, which is a single-stranded RNA virus – as are coronaviruses. Pharmaceutical Technology covered the news.